The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Following recent publications and anticipating the readout from its NILE study next year, the company plans to make the case that its liquid biopsy approach performs as well as tissue tests.
Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.
BBI has developed Morffi ™ signal enhancement technology which has the potential to enhance the sensitivity of lateral flow immunoassays. In this paper, we demonstrate the increased sensitivity that can be achieved using this new signal enhancement technology, comparing it with traditional BSA blocking in a brain natriuretic peptide assay. The results show that this proprietary technology offers a 10-fold improvement in the limit of detection over the BSA-blocked control, highlighting its potential for enhancing both current and future lateral flow tests.
Freeze-drying (lyophilization) is becoming increasingly popular with IVD test manufacturers looking to simplify assay handling and processing. Biofortuna is a leading supplier of freeze-dried tests, and has a wealth of expertise in transforming molecular diagnostic reagents into instantly soluble freeze-dried pellets. This white paper outlines the key considerations when developing a freeze-dried IVD test and discusses some of the strategies that can be used to ensure rapid, successful and cost-effective assay development.
Clinical laboratories are increasingly adopting molecular assays as an alternative to the tedious, time-consuming stool cultures that have long been the mainstay for testing patients who might have infectious diarrhea or conditions such as Salmonella or Campylobacter. With an estimated 1.7 billion cases of childhood diarrheal disease occurring annually around the world, this is a significant advance for gastroenteritis testing.
